Genetic suppression and replacement

Details Genetic suppression and replacement Genetic suppression and replacement

2006-11-21

2006-11-21

Epps-Ford, Janet L. (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S006120, C435S091310, C435S091100, C435S320100, C435S325000, C435S375000, C536S023100, C536S023200, C536S024310, C536S024500

Reexamination Certificate

active

07138378

ABSTRACT:
A strategy for suppressing specifically or partially specifically an endogenous gene and introducing a replacement gene, said strategy comprising the steps of:1. providing suppressing nucleic acids or other suppression effectors able to bind to an endogenous gene, gene transcript or gene product to be suppressed and2. providing genomic DNA or cDNA (complete or partial) encoding a replacement gene wherein the suppressing nucleic acids are unable to bind to equivalent regions in the genomic DNA or cDNA to prevent expression of the replacement gene.The replacement nucleic acids have modifications in one or more third base (wobble) positions such that replacement nucleic acids still code for the wild type or equivalent amino acids.

REFERENCES:
patent: 5087617 (1992-02-01), Smith
patent: 5223391 (1993-06-01), Coen et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5246921 (1993-09-01), Reddy et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5582972 (1996-12-01), Lima et al.
patent: 5814500 (1998-09-01), Dietz
patent: 5834440 (1998-11-01), Goldenberg et al.
patent: 5977296 (1999-11-01), Nielsen et al.
patent: 6025127 (2000-02-01), Sidransky
patent: 6077705 (2000-06-01), Duan et al.
patent: 6326174 (2001-12-01), Joyce et al.
patent: 6482803 (2002-11-01), Roth et al.
patent: 414134 (1991-02-01), None
patent: 0475623 (1992-03-01), None
patent: 92/12262 (1992-07-01), None
patent: 93/12257 (1993-06-01), None
patent: 93/21202 (1993-10-01), None
patent: 94/03596 (1994-02-01), None
patent: 94/11494 (1994-05-01), None
patent: 94/22487 (1994-10-01), None
patent: 94/26887 (1994-11-01), None
patent: 95/03335 (1995-02-01), None
patent: 95/34573 (1995-12-01), None
patent: 97/11169 (1997-03-01), None
patent: 97/32024 (1997-09-01), None
patent: 97/37014 (1997-10-01), None
Hart et al. The introduction of two silent muations into a CFTR cDNA construct allows improved detection of exogenous mRNA in gene transfer experiments. Human Molecular Genetics, 1995, vol. 4, No. 0, pp. 1597-1602.
Stanley Crooke, Antisense Research and Applications, Chapter 1, Basic Principles of Antisense Therapeutics, Springer-Verlag Press, Berlin, Heidelberg, New York, p. 3. Jul. 1998.
Andrea D. Branch, A good antisense molecule is hard to find, TIBS, 47-48, Feb. 1998.
Marshall et al. Science, vol. 269, pp. 1050-1055. May 1995.
Gómez-Navarro et al. European Journal of Cancer, vol. 35, No. 6, pp. 867-885 (1999).
Robinson-Benion et al. Gene transplantation: Combined antisense inhibition and gene replacement strategies. Apr. 1994, Leukemia, vol. 8, pp. s152-s155.
Burke et al. Hairpin and Hammerhead ribozymes: how different are they? Biochemical Society Transcations (2002) vol. 30, part 6, pp. 1116-1118.
Takagi et al. Mechanisim of action of hammerhead ribozymes and their applications in vivo:rapid identification of functional genes in the post-genome era by novel hybrid ribozyme libraries. (2002) Biochemical Society, vol. 30(6), pp. 1145-1149.
Robinson-Benion et al., “Gene Transplantation: Combined Antisense Inhibition and Gene Replacement Strategies”, Sep. 27, 1993, pp. S152-S155.
Hart et al., The introduction of two silent mutations into a CFTR cDNA construct . . . , Human Molecular Genetics, vol. 4, No. 9, 1995, pp. 1597-1602.
Herrmann, Cancer Gene Therapy: Principles, Problems, and Perspectives,J. Mol. Med.(1995) vol. 73: 157-163.
Crooke, “Basic Principles of Antisense Therapeutics,”Antisense Research and Application, pp. 1-50.
Branch, “A good antisense molecule is hard to find,”TIBS 23, (1998), pp. 45-50.
Special News Report: “Gene Therapy's Growing Pains,”Science(1995) vol. 269, pp. 1050-1055. Marshall.
Gomez-Navarro et al., “Gene Therapy for Cancer,”European Journal of Cancer(1999) vol. 35, No. 6, pp. 867-885.
Denman et al., “Ribozyme mediated degradation of β-amyloid peptide precursor mRNA in COS-7 cells,”Nucleic Acids Research, Oxford University Press, (1994) vol. 22, No. 12, pp. 2375-2382.
Lieber et al., “Adenovirus-Mediated Expression of Ribozymes in Mice,”Journal of Virology(1996) vol. 70, No. 5, pp. 3153-3158.
Kashani-Sabet et al., “Suppression of Neoplastic Phenotype in Vivo by an Anti-ras Ribozyme,”Cancer Research(1994), vol. 54, pp. 900-902.
Larsson et al., “Reduced β2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme,”Nucleic Acids Research(1994) vol. 22, No. 12, pp. 2242-2248.
Khillan et al., “Partial rescue of a lethal phenotype of fragile bones in transgenic mice with a chimeric antisense gene directed against a mutated collagen gene,”Proc. Natl. Acad. Sci. USA(1994) vol. 91, pp. 6298-6302.
Ohkawa et al., “Ribozymes: From Mechanistic Studies to Applications in Vivo,”J. Biochem.(1995) vol. 118, pp. 251-258.
Cotten et al. “Ribozyme mediated destruction of RNA in vivo,”The EMBO Journal(1989) vol. 8, No. 12, pp. 3861-3866.
Kariko et al., “Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA,”FEBS Letter(1994) vol. 352, pp. 41-44.
Ohta et al., “Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells,”Nucleic Acids Research(1996) vol. 24, No. 5, pp. 938-942.
Chowrira et al., “In Vitro and in Vivo Comparison of Hammerhead, Hairpin, and Hepatitis Delta Virus Self-processing Ribozyme Cassettes,”The Journal of Biological Chemistry(1994) vol. 269, No. 41, pp. 25856-25864.
Little et al., “Generation of a Mammalian Cell Line Deficient in Glucose-regulated Protein Stress Induction through Targeted Ribozyme Driven by a Stress-inducible Promoter,”The Journal of Biological Chemistry(1995) vol. 270, No. 16, pp. 9526-9534.
Cameron et al., “Specific gene suppression by engineered ribozymes in monkey cells,”Proc. Natl. Acad. Sci. USA(1989) vol. 86, pp. 9139-0143.
Kobayashi et al., “Specificity of Ribozyme Designed for Mutated DHFR mRNA,”Biochemical Pharmacology(1994) vol. 47, No. 9, pp. 1607-1613.
Lieber et al., “Selection of Efficient Cleavage Sites in Target RNAs by Using a Ribozyme Expression Library,”Molecular and Cellular Biology(1995) vol. 15, No. 1, pp. 540-551.
Blaese et al., “Strategies for Gene Therapy.”Pathol. Biol.(Paris), 1993, 41(8):672-6.
Bordignon et al., “Transfer of the ADA Gene into Bone Marrow Cells and Peripheral Blood Lymphocytes for the Treatment of Patients Affected by ADA-Deficient SCID.”Hum. Gene Ther., 1993, 4(4): 513-20.
Ch'ng et al., “Antisense RNA Complementary to 3' Coding and Noncoding Sequences of Creatine Kinase is a Potent Inhibitor of Translation in vivo.”Proc. Natl. Acad. Sci. USA, 1989, 86: 10006-10010.
Chertkov et al., “The Hematopoietic Stromal Microenvironment Promotes Retrovirus-Mediated Gene Transfer into Hematopoietic Stem Cells.”Stem Cells, 1993, 11(3): 218-27.
Cournoyer et al., “Gene Therapy of the Immune System.”Ann. Rev. Immunol., 1993, 11: 297-329.
Couture et al., “Retroviral Vectors Containing Chimeric Promoter/Enhancer Elements Exhibit Cell-Type-Specific Gene Expression.”Hum. Gene Ther., 1994, 5(6): 667-77.
Fairbanks et al., “Biochemical and Immunological Status Following Gene Therapy and PEG-ADA Therapy for Adenosine Deaminase (ADA) Deficiency.”Adv. Exp. Med. Biol., 1994, 370: 391-4.
Friedmann, “Overcoming the Obstacles to Gene Therapy.”Sci. Am., Jun. 1997, 96-101.
Grossman et al., “Successful ex vivo Gene Therapy Directed to Liver in a Patient with Familial Hypercholesterolaemia.”Nature Gen., 1994, 6: 335-341.
Hershfield, “PEG-ADA Replacement Therapy for Adenosine Deaminase Deficiency: An Update After 8.5 Years.”Clin. Immunol. Immunopathol., 1995, 76: S228-32.
Hughes et al., “Delivery of a Secretable Adenosine Deaminase Through Microcapsules- A Novel Approach to Somatic gene therapy.”Hum. Gene Ther., 1994, 5(12

Affiliated with

Also associated with

Rating

Genetic suppression and replacement does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Genetic suppression and replacement, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetic suppression and replacement will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3660089